SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Brandon D. Ayres, MD, discusses data from the SAHARA trial, which evaluated patients with dry eye disease and meibomian gland dysfunction.
The randomized controlled study compared the TearCare system with 6 months of twice-daily Restasis (cyclosporine ophthalmic emulsion 0.05%, Allergan). The trial’s primary endpoints included tear break up time and the ocular surface disease index or patient reported outcomes of their dry eye symptoms.
At 6 months, patients showed a better tear break up time using the TearCare